Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT).

Full DD Report for RCKT

You must become a subscriber to view this report.


Recent News from (NASDAQ: RCKT)

Rocket Pharmaceuticals Announces Strategic Research Collaboration
- Agreement to Support the Advancement of Fanconi Anemia and Pyruvate Kinase Deficiency Gene Therapy Research - Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, and the Stanford University School of Medic...
Source: Business Wire
Date: May, 17 2018 07:00
Institutional Top Ideas Series: Opaleye Management
In the last entry of this series, we took a look at top ideas from Ra Capital Management, the best performing fund we´ve come across so far with heavily concentrated positions in their top ideas. Going forward, I hope to continue to delve into the portfolios of successful hedge funds ...
Source: SeekingAlpha
Date: May, 17 2018 01:52
Reader Inquiry: Is There Further Upside Ahead For Rocket Pharmaceuticals?
Shares of gene therapy newcomer Rocket Pharmaceuticals ( RCKT ) have risen by over 80% year to date. The formerly private company came into existence (on the stock exchange) after a merger with floundering biotech firm Inotek Pharma in which shareholders of the former owned 81% of the combined...
Source: SeekingAlpha
Date: May, 15 2018 14:48
Rocket Pharmaceuticals Appoints Gayatri R. Rao, M.D., J.D., Former U.S. Food and Drug Administration Director of the Office of Orphan Products Development, as Vice President, Regulatory Policy and Patient Advocacy
Rocket Pharmaceuticals, Inc . (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announced the appointment of Gayatri R. Rao, M.D., J.D., as Vice President, Regulatory Policy and Patient Advocacy. In this new role, Dr. Rao will provide c...
Source: Business Wire
Date: May, 15 2018 07:00
Rocket Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights
Four Gene Therapy Programs Potentially in Clinic in 2019 with Clinical Data from up to Two Programs Regulatory Submissions on Schedule for LAD-I, PKD and AAV Programs Over the Next 12 Months Development of a Long-term Sustainable Growth Company Leveraging a Multi-Platform Approach...
Source: Business Wire
Date: May, 11 2018 07:00
Rocket Pharmaceuticals to Present at Upcoming Investor Conferences
Rocket Pharmaceuticals, Inc . (NASDAQ:RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announced that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will present a company overview at the following investor conferences: ...
Source: Business Wire
Date: May, 08 2018 07:00
Rocket Pharmaceuticals Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
- Multiple presentations at ASGCT Highlight Potential of Rocket’s Multi-Platform Approach to Address Devastating Rare Diseases with Gene Therapy - - Updated Data of Ongoing Phase 1/2 Trial in Fanconi Anemia (FA) Showcased at Presidential Symposium - Rocket Pharmaceutic...
Source: Business Wire
Date: April, 30 2018 14:30
Novartis takeout of AveXis stokes buying in gene therapy players
Gene therapy developers bluebird bio (NASDAQ: BLUE ) and Audentes Therapeutics (NASDAQ: BOLD ) are up  8%  and  10%  premarket, respectively, both on light volume on the heels of Novartis' $8.7B bid for AveXis. More news on: bluebird bio, Inc., Audentes Therapeutics, In...
Source: SeekingAlpha
Date: April, 09 2018 07:19
Midday Gainers / Losers (4/5/2018)
Gainers: LFIN +81% . NETE +26% . NVCN +26% . I +18% . VERI +18% . VTNR +12% . SNOA +14% . FTFT +15% . PLSE +14% . LEDS +13% . More news on: LongFin Corp, Net Element International, Inc., Neovasc Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 05 2018 12:43
Rocket Pharmaceuticals Reports Full Year 2017 Financial Results and Operational Highlights
- Enters 2018 as a Public Company with Solid Financial Position Following Successful Completion of Merger with Inotek Pharmaceuticals and Subsequent Follow-on Offering - - Multiple Milestones Expected in 2018, with Additional Data in Fanconi Anemia, Disclosure of AAV Program, and Sever...
Source: Business Wire
Date: March, 06 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1721.9719.9322.403619.61866,810

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2164,991119,31654.4696Short
2018-05-1864,39796,22166.9261Short
2018-05-17142,622300,50147.4614Short
2018-05-16193,955334,37158.0059Short
2018-05-15108,156201,49553.6768Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RCKT.


About Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)

Logo for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $708,054,353 - 05/11/2018
  • Issue and Outstanding: 39,402,023 - 03/01/2018

 


Recent Filings from (NASDAQ: RCKT)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 07 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 07 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 07 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: RCKT)

Daily Technical Chart for (NASDAQ: RCKT)


Stay tuned for daily updates and more on (NASDAQ: RCKT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: RCKT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RCKT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of RCKT and does not buy, sell, or trade any shares of RCKT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/